Navigation Links
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function
Date:11/7/2010

NEW YORK, Nov. 7, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months. For a third primary endpoint, the rate of DAS28-4(ESR) <2.6, a measure of disease remission, treatment with tasocitinib resulted in a numerically greater, but not statistically significant difference from placebo at three months.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

In ORAL Solo, a similar frequency of adverse events was seen across all treatment groups. Serious adverse events were reported in 4.1 percent of patients. Additionally, decreases in neutrophil count and hemoglobin and an increase in cholesterol occurred by month three. These changes tended to stabilize thereafter. No new safety signals were detected.

"We are encouraged by the statistically significant and clinically meaningful improvements we observed in a proportion of patients treated with tasocitinib monotherapy in ORAL Solo," said Roy Fleischmann, MD, Clinical Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas.  "Further research into additional treatment options for patients with moderately to severely active RA is important, and we look forward to seeing the results of the additional Phase 3 ORAL trials of tasocitinib."

ORAL Sequel (1024), an open label, follow-up Phase 2/3 study,
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
2. Genoptix Reports Operating Results for the Third Quarter and First Nine Months of 2010
3. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
4. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
5. GREENGUARDs First Exhibit at HEALTHCARE DESIGN.10 to Help Architects and Designers Specify Healthier Products More Easily and Efficiently
6. CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance
7. Endologix Announces First Clinical Implant of Ventana™ Stent Graft
8. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
9. PAREXEL Reports First Quarter Fiscal Year 2011 Financial Results
10. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
11. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Dr. Michael Gabriel of a prominent Staten ... study, which shows how grief in pregnancy may cause obesity ... According to US News , "Unborn children ... others to grow up overweight or obese, even if that ... specific types of stress that caused obesity: "Children whose biological ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... release its second quarter 2014 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, July ... quarter and other business developments. Interested parties ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Inc. and Cedarlane today announced that they have entered ... distribute high value reagent proteins produced by Pfenex to ... products initially distributed will be vaccine carrier proteins such ... related growth factors including G-CSF and Interferon beta 1-b. ...
... Research Group, Inc. recently published its TreatmentTrends®: Vascular ... based on online survey results from ... interventional nephrologists). It provides an in-depth view of the ... to both vascular access placement and maintenance.   ...
Cached Medicine Technology:Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation 2Latest BioTrends Report Provides Comprehensive Market Landscape of the Dialysis Vascular Access Market 2
(Date:7/26/2014)... As the category creator and world leader ... Xoçai is to transform and improve individual ... products. One such unique element is XoVita™, a ... blueberries, an ingredient combination exclusive to Xoçai. This ... all of Xoçai products and provides a wide-ranging ...
(Date:7/25/2014)... 2014 2014 Deep Research ... Chromatography Industry” is a professional and in-depth ... Gel Permeation Chromatography market. The report provides ... Permeation Chromatography definition, classification, application, and industry ... This research covers the international market analysis, ...
(Date:7/25/2014)... 2014 American motor vehicle owners who ... can pay higher premiums for vehicle insurance on average. ... network to provide SR22 insurance for high risk motorists ... different coverage network of local agencies providing direct price ... platform now publicly available for any car owner to ...
(Date:7/25/2014)... Ticket Down announces that they ... Guinness International Champions Cup match between international soccer powerhouses ... on Sunday, July 27th. This well-known ticket ... SOCCER-2014 for added savings. , 2014 is turning out ... in North America. Countless international soccer teams have been ...
(Date:7/25/2014)... 2014 Sport Court® provided ... Nike National Invitational Tournament (NIT) in Chicago ... Junior National Tournament (USJN) in Washington D.C. at ... for these prestigious national tournaments included 44 Sport Court ... of playing surface at McCormick Place for the NIT, ...
Breaking Medicine News(10 mins):Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2
... , , ... outdoor ground-level ozone, microscopic particle pollution like smoke and smog, ... is sensitive to these airborne contaminants to experience shortness of ... and cause lung irritation(1). According to AIRNow.gov(2), a government-developed index ...
... is providing valuable new clues into cancer,s deadliest behavior -- ... spreading throughout the body. Duke University biologist David ... of a single cell in the developing body of a ... one of its jobs is to connect the developing animal,s ...
... EVANSTON, Ill. --- Anyone with an MP3 device -- just about every ... a notion of the majesty of music, of the primal place it ... be seen simply as stuff of the soul -- a frill that ... Northwestern University study. The study shows that musicians -- trained ...
... , , Congressman Chaka Fattah (D-PA) releases ... healthcare system. , , WASHINGTON, Aug. 17 "We ... If real reform is to take place it must include a public option. ... in any major city they deliberate how they will get to their destination. ...
... , NEWINGTON, N.H. Aug. 17 ... atmosphere have struck a chord with consumers, is being honored in ... private companies in America. , , (Logo: ... number 471 on the lnc. 500, which ranks the nation,s top ...
... , , , , ... community, announces its donation of a fully furnished two bedroom apartment ... their families to stay for free while undergoing care at the ... and availability, the managing partners of Presidential Towers felt that this ...
Cached Medicine News:Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 2Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 3Health News:Cancer's break-in tools possibly identified at Duke 2Health News:Taking up music so you can hear 2Health News:Taking up music so you can hear 3Health News:Planet Fitness Soars to Inc. 500 2Health News:Presidential Towers Donates Apartment to the University of Illinois Medical Center 2
PDA format of the well-known standard antimicrobial reference....
PDA application providing a complete guide for the diagnosis and management of electrolyte disorders....
Contains the most common procedures from all orthopedic sub-specialties organized by body area....
Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
Medicine Products: